Journal profile · GASTROENTEROLOGY & HEPATOLOGY
Crohns & Colitis 360
ISSN 2631-827X · Oxford University Press · United Kingdom
Crohns & Colitis 360: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 4 (journal website); fully open access; APC about USD 3,217; median 154 days to acceptance (92 articles, last 24 months); 37 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Crohns & Colitis 360 is published by Oxford University Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Inflammatory Bowel Disease, Microscopic Colitis and Rheumatoid Arthritis Research and Therapies, together about 59.2% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Crohn's & Colitis 360 supports the mission of the Crohn's & Colitis Foundation by publishing research that will improve the quality of life of patients with inflammatory bowel disease (IBD) and bring us closer to cures. This peer-reviewed, online-only, open access journal publishes a wide range of content focused on state-of-the-art holistic care for patients with IBD alongside the latest research to advance prevention, treatment and cures. Crohn's & Colitis 360 releases four issues per year and provides a forum for the dissemination of novel insights and innovations across key disciplines involved in adult and pediatric IBD care. Articles include original research (basic, translational and clinical), hot topic reviews, best practice summaries, care pathways and practice guidelines, care tools, and multimedia content. The journal reflects the broad diversity of the IBD field and aims to support patient care through research, practice, and education. It also prioritizes patient-driven and advocacy-driven articles, using patient-centric language. All accepted manuscripts have a patient/community facing abstract that highlights impactful findings, ensuring that the research is accessible and meaningful to both healthcare providers and patients alike. Crohn's & Colitis 360 is an official journal of the Crohn's & Colitis Foundation. We invite you to read more about the Foundation’s mission and core values. Indexing Crohn's & Colitis 360 is indexed in PMC. All articles from the journal are fully indexed and available. Journal metrics Citation metrics Clarivate 2025 Impact Factor 3.0 2025 5 Year Impact Factor 2.9 Gastroenterology & Hepatology (Rank by Impact Factor) 67/153 Scopus 2025 CiteScore 4.0 Gastroenterology (Rank by CiteScore) 74/176 About metrics Disclaimer Statements of fact and opinion in the articles in Crohn's & Colitis 360 are those of the respective authors and contributors and not of the Journal, Crohn's & Colitis Foundation, or Oxford University Press, unless otherwise expressly indicated. Neither Oxford University Press, Crohn's & Colitis Foundation, nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included.
From the journal's Aims & Scope
Research area (LetPub): GASTROENTEROLOGY & HEPATOLOGY
Editor-in-chief Aline CharabatyPublisher website
Editorial board by country: none in mainland China; most named United States 29, Brazil 2, Japan 1, South Korea 1, India 1 (37 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Inflammatory Bowel DiseaseBiochemistry, Genetics and Molecular Biology38.4%
- Microscopic ColitisMedicine14.6%
- Rheumatoid Arthritis Research and TherapiesMedicine6.2%
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology5.5%
- Autoimmune and Inflammatory DisordersMedicine4.9%
- Pregnancy and Medication ImpactMedicine3.9%
- Gastrointestinal motility and disordersMedicine3.3%
- Clostridium difficile and Clostridium perfringens researchMedicine2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Gastroenterology & Hepatology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Gastroenterology & Hepatology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 4Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.9Publisher website ·
- CiteScore 2026-06
- 4LetPub ·
- CiteScore (publisher) 2025
- 4Publisher website ·
- SJR 2026-06
- 1LetPub ·
- SNIP 2026-06
- 0.87LetPub ·
- h-index
- 25OpenAlex ·
- i10-index
- 120OpenAlex ·
- 2-year mean citedness
- 2.17OpenAlex ·
- Self-citation rate
- 3.3%LetPub ·
- Share of gold OA articles
- 91.75%LetPub ·
Volume
- Articles per year
- 74LetPub ·
Articles by year OpenAlex count · 576 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 81 | 81 | 6 |
| 2025 | 37 | 37 | 84 |
| 2024 | 93 | 93 | 367 |
| 2023 | 81 | 81 | 625 |
| 2022 | 51 | 51 | 511 |
| 2021 | 83 | 83 | 805 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
154 daysMedian, submission to acceptance · P25–P75 119 days – 214 days
- Acceptance to online
- median 58 days (92 articles)
- Submission to online
- median 227 days
- Sample
- 92 articles with submission and acceptance dates (195 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,217 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 3,378 | — | — | |
| LetPub | USD 3,217 | Yes | — | |
| Publisher website | USD 3,625 | — | — |
Other charges and waivers (author guidelines)
- Discounts
- No discounts
- Submission fee
- USD 3,625
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 3–5
- Manuscript length
- ≤ 1,000 words
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
- Highlights
- Required
- Cover letter
- Required
Article types accepted11, with length limits
- commentaryThe Editors endeavor to have Crohn’s & Colitis 360 reflect the broad diversity of the IBD field and how a comprehensive approach can support patient care throug…Length not stated
- communicationsCommunications Communications follow a similar format to letters to the editor. These should be framed as commentaries on published work or initial observations…Length not stated
- editorialThe Editors endeavor to have Crohn’s & Colitis 360 reflect the broad diversity of the IBD field and how a comprehensive approach can support patient care throug…Length not stated
- innovations in care deliveryInnovations in Care Delivery Original articles presenting designs for, or data on, novel management strategies to deliver care to patients with IBD e.g. descrip…Length not stated
- invited reviewsInvited Reviews Short (1,000 words, 5 references) on a topic in basic or clinical science that may impact IBD management in the next 5-10 years. These will be i…Length not stated
- letters to the editorThe Editors endeavor to have Crohn’s & Colitis 360 reflect the broad diversity of the IBD field and how a comprehensive approach can support patient care throug…Length not stated
- observations & researchObservations & Research Original manuscripts of data on basic science or clinical observations or interventions with descriptive results and analysis. Example w…Length not stated
- original articleThe Editors endeavor to have Crohn’s & Colitis 360 reflect the broad diversity of the IBD field and how a comprehensive approach can support patient care throug…Length not stated
- original research articleThe Editors endeavor to have Crohn’s & Colitis 360 reflect the broad diversity of the IBD field and how a comprehensive approach can support patient care throug…Length not stated
- patient summaryPatient Summary These are short (500 words) summaries of IBD topics written with the lay person in mind.Length not stated
- reviewThe Editors endeavor to have Crohn’s & Colitis 360 reflect the broad diversity of the IBD field and how a comprehensive approach can support patient care throug…main text ≤ 1,000 words
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Plagiarism
- Authorship Authorship
Each person listed as an author is expected to follow the authorship criteria put forth by the ICMJE. Deceased persons who meet the criteria for inclusion as coauthors should be so included, with an Author Information note indicating the date of death. Authorship is limited to those who have made a significant contribution to the design and execution of the work described. Any contributors whose p…
Source ↗Publisher website ·- Conflicts of interest Policies on Conflicts of Interest
Crohn's & Colitis 360 is committed to making transparent the Journal’s policies on Conflict of Interest as they relate to authors, reviewers, and editors. Authors should familiarize themselves with the below points as well as COPE’s Guidelines on Good Publication Practice before committing to working with the Journal. Conflicts in regard to publication can occur when a competing interest may influ…
Source ↗Publisher website ·- Publication ethics Ethical Considerations
A submitted manuscript must be an original contribution not previously published (except as an abstract or preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of the publisher. Deposition of manuscripts prior to submission on community preprint servers or on conferenc…
Source ↗Publisher website ·- License & copyright License to Publish
Upon receipt of accepted manuscripts at Oxford University Press authors will be invited to complete an online copyright license to publish form. Please note that by submitting a manuscript for consideration for publication, you confirm that you are the corresponding/submitting author and that Oxford University Press may retain your email address for the purpose of communicating with you about the …
Source ↗Publisher website ·- Open access Open Access Publication Fee Information
Crohn’s & Colitis 360 is a fully open access journal, and all articles are published in the journal under an open access license immediately upon publication. You will need to pay an open access charge to publish under an open access license. Details of the open access licenses and open access charges. Fees for invited Editorials will be waived. Journal (required) Please select Academic MedicineAc…
Source ↗Publisher website ·- Peer review Peer Review
Double-anonymized peer review. Model summary
The Editors read all manuscript submissions. All manuscripts that meet the quality standards, are felt to advance the field, and adhere to the scope of the Journal are assigned to an Associate Editor and sent to outside experts for peer review using a double-anonymized system, meaning that authors’ identities are hidden from reviewers and reviewers’ identities are hidden from authors. The Editors …
Source ↗Publisher website ·- Plagiarism Plagiarism
All papers must be free of plagiarism. Plagiarism includes the unreferenced use of the author’s own work or ideas or the work or ideas of others, either published or unpublished. It may occur at any stage of the development of a manuscript and it applies to electronic versions of the work. Authors should consult the Committee on Publication Ethics’ (COPE) Guidelines on Good Publication Practice if…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Oxford University Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2631-827X
- Society / sponsor
- Crohn's & Colitis Foundation
- Latest issue on the website
- Volume 8, Issue 3 (July 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Crohns & Colitis 360
What CAS zone is Crohns & Colitis 360 in?
In the 2025 upgraded edition of the CAS Journal Ranking, Crohns & Colitis 360 is in Zone 4 of Medicine, and in Zone 4 of the minor category Gastroenterology & Hepatology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Crohns & Colitis 360?
The journal's website gives an impact factor of 4 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4, h-index 25.
How long does peer review take at Crohns & Colitis 360?
Based on the dates recorded on 92 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 154 days (interquartile range 119–214 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Crohns & Colitis 360?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 3–5; Manuscript length: ≤ 1,000 words; Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional; Highlights: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Crohns & Colitis 360 based?
Of the 37 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (29), Brazil (2) and Japan (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Crohns & Colitis 360?
According to LetPub and DOAJ records, Crohns & Colitis 360 is indexed in ESCI, Scopus and DOAJ. The journal's website also lists PMC; that list has not been checked against each database.
Is Crohns & Colitis 360 open access, and what is the APC?
Crohns & Colitis 360 is a fully open-access journal. APC about USD 3,217.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .